Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

139 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pembrolizumab plus eribulin in hormone-receptor-positive, HER2-negative, locally recurrent or metastatic breast cancer (KELLY): An open-label, multicentre, single-arm, phase Ⅱ trial.
Pérez-García JM, Llombart-Cussac A, G Cortés M, Curigliano G, López-Miranda E, Alonso JL, Bermejo B, Calvo L, Carañana V, de la Cruz Sánchez S, M Vázquez R, Prat A, R Borrego M, Sampayo-Cordero M, Seguí-Palmer MÁ, Soberino J, Malfettone A, Schmid P, Cortés J. Pérez-García JM, et al. Eur J Cancer. 2021 May;148:382-394. doi: 10.1016/j.ejca.2021.02.028. Epub 2021 Mar 29. Eur J Cancer. 2021. PMID: 33794440 Clinical Trial.
New approaches and targets in advanced colorectal cancer.
Macarulla T, Capdevila J, Perez-Garcia J, Ramos FJ, Elez ME, Markman B, Ruiz-Echarri M, Tabernero J. Macarulla T, et al. Eur J Cancer. 2009 Sep;45 Suppl 1:79-88. doi: 10.1016/S0959-8049(09)70019-X. Eur J Cancer. 2009. PMID: 19775607 No abstract available.
The beautiful history of pertuzumab.
Perez-Garcia J, Muñoz-Couselo E, Ortega V, Cortes J. Perez-Garcia J, et al. Expert Rev Anticancer Ther. 2012 Jun;12(6):703-5. doi: 10.1586/era.12.46. Expert Rev Anticancer Ther. 2012. PMID: 22716485 No abstract available.
A roadmap for accelerated drug approval in breast cancer?
Perez-Garcia J, Cortes J. Perez-Garcia J, et al. Lancet Oncol. 2012 Sep;13(9):850-1. doi: 10.1016/S1470-2045(12)70367-4. Epub 2012 Aug 9. Lancet Oncol. 2012. PMID: 22884504 No abstract available.
RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer.
Serra V, Eichhorn PJ, García-García C, Ibrahim YH, Prudkin L, Sánchez G, Rodríguez O, Antón P, Parra JL, Marlow S, Scaltriti M, Pérez-Garcia J, Prat A, Arribas J, Hahn WC, Kim SY, Baselga J. Serra V, et al. J Clin Invest. 2013 Jun;123(6):2551-63. doi: 10.1172/JCI66343. Epub 2013 May 1. J Clin Invest. 2013. PMID: 23635776 Free PMC article.
Adjuvant bevacizumab: positive data from a negative trial.
Perez-Garcia J, Cortes J. Perez-Garcia J, et al. Lancet Oncol. 2013 Sep;14(10):910-1. doi: 10.1016/S1470-2045(13)70378-4. Epub 2013 Aug 7. Lancet Oncol. 2013. PMID: 23932547 No abstract available.
139 results